KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Accured Expenses (2018 - 2025)

Vir Biotechnology's Change in Accured Expenses history spans 8 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 120.84% year-over-year to $10.1 million; the TTM value through Dec 2025 reached -$9.5 million, up 85.15%, while the annual FY2025 figure was -$9.5 million, 85.15% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $10.1 million at Vir Biotechnology, up from -$14.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $433.6 million in Q1 2022 and bottomed at -$288.2 million in Q2 2022.
  • The 5-year median for Change in Accured Expenses is -$16.5 million (2021), against an average of -$19.5 million.
  • The largest YoY upside for Change in Accured Expenses was 2402.84% in 2022 against a maximum downside of 8228.76% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $72.0 million in 2021, then tumbled by 212.04% to -$80.7 million in 2022, then surged by 48.02% to -$41.9 million in 2023, then decreased by 15.65% to -$48.5 million in 2024, then skyrocketed by 120.84% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Change in Accured Expenses are $10.1 million (Q4 2025), -$14.2 million (Q3 2025), and -$24.2 million (Q2 2025).